Rathbones Group PLC Lowers Stock Holdings in Astrazeneca Plc $AZN

Rathbones Group PLC lowered its position in shares of Astrazeneca Plc (NYSE:AZN) by 35.8% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 7,537 shares of the company’s stock after selling 4,200 shares during the period. Rathbones Group PLC’s holdings in Astrazeneca were worth $693,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Binnacle Investments Inc raised its holdings in shares of Astrazeneca by 21.8% during the 3rd quarter. Binnacle Investments Inc now owns 660 shares of the company’s stock worth $51,000 after acquiring an additional 118 shares in the last quarter. Chapin Davis Inc. grew its holdings in shares of Astrazeneca by 3.3% in the third quarter. Chapin Davis Inc. now owns 3,795 shares of the company’s stock valued at $291,000 after purchasing an additional 120 shares in the last quarter. 44 Wealth Management LLC grew its holdings in shares of Astrazeneca by 0.7% in the third quarter. 44 Wealth Management LLC now owns 16,722 shares of the company’s stock valued at $1,283,000 after purchasing an additional 124 shares in the last quarter. CoreCap Advisors LLC increased its position in Astrazeneca by 30.6% in the third quarter. CoreCap Advisors LLC now owns 534 shares of the company’s stock worth $41,000 after purchasing an additional 125 shares during the last quarter. Finally, Highline Wealth Partners LLC increased its position in Astrazeneca by 32.0% in the third quarter. Highline Wealth Partners LLC now owns 532 shares of the company’s stock worth $41,000 after purchasing an additional 129 shares during the last quarter. 20.35% of the stock is currently owned by hedge funds and other institutional investors.

Astrazeneca Stock Up 1.8%

NYSE AZN opened at $204.44 on Thursday. The company has a quick ratio of 0.72, a current ratio of 0.94 and a debt-to-equity ratio of 0.51. Astrazeneca Plc has a 52 week low of $122.48 and a 52 week high of $212.71. The firm has a market cap of $317.06 billion, a price-to-earnings ratio of 31.21, a PEG ratio of 1.53 and a beta of 0.35.

Astrazeneca Announces Dividend

The company also recently declared a dividend, which was paid on Monday, March 23rd. Investors of record on Friday, February 20th were issued a dividend of $1.595 per share. This represents a yield of 156.0%. The ex-dividend date was Friday, February 20th. Astrazeneca’s dividend payout ratio is presently 66.26%.

Wall Street Analysts Forecast Growth

AZN has been the subject of several research reports. Citigroup started coverage on shares of Astrazeneca in a research report on Tuesday, January 27th. They set a “buy” rating for the company. Deutsche Bank Aktiengesellschaft restated a “sell” rating on shares of Astrazeneca in a report on Friday, February 6th. TD Cowen restated a “buy” rating on shares of Astrazeneca in a research report on Wednesday, March 18th. Weiss Ratings began coverage on shares of Astrazeneca in a report on Wednesday, March 11th. They issued a “buy (b)” rating for the company. Finally, HSBC reiterated a “buy” rating and issued a $108.00 price target on shares of Astrazeneca in a research report on Wednesday, December 10th. Nine equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $95.75.

Astrazeneca Company Profile

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.